Alzamend Neuro (ALZN) Competitors $2.44 +0.04 (+1.67%) Closing price 04:00 PM EasternExtended Trading$2.44 0.00 (-0.20%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALZN vs. MAAQ, GBIO, OKUR, RNTX, DYAI, BDRX, MIRA, NNVC, TENX, and JATTShould you be buying Alzamend Neuro stock or one of its competitors? The main competitors of Alzamend Neuro include Mana Capital Acquisition (MAAQ), Generation Bio (GBIO), OnKure Therapeutics (OKUR), Rein Therapeutics (RNTX), Dyadic International (DYAI), Biodexa Pharmaceuticals (BDRX), MIRA Pharmaceuticals (MIRA), NanoViricides (NNVC), Tenax Therapeutics (TENX), and JATT Acquisition (JATT). These companies are all part of the "pharmaceutical products" industry. Alzamend Neuro vs. Its Competitors Mana Capital Acquisition Generation Bio OnKure Therapeutics Rein Therapeutics Dyadic International Biodexa Pharmaceuticals MIRA Pharmaceuticals NanoViricides Tenax Therapeutics JATT Acquisition Mana Capital Acquisition (NASDAQ:MAAQ) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation. Is MAAQ or ALZN more profitable? Mana Capital Acquisition's return on equity of 0.00% beat Alzamend Neuro's return on equity.Company Net Margins Return on Equity Return on Assets Mana Capital AcquisitionN/A N/A N/A Alzamend Neuro N/A -181.34%-116.84% Do analysts rate MAAQ or ALZN? Alzamend Neuro has a consensus price target of $180.00, suggesting a potential upside of 7,277.05%. Given Alzamend Neuro's stronger consensus rating and higher probable upside, analysts clearly believe Alzamend Neuro is more favorable than Mana Capital Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mana Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Alzamend Neuro 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better earnings & valuation, MAAQ or ALZN? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMana Capital AcquisitionN/AN/AN/AN/AN/AAlzamend NeuroN/AN/A-$4.51MN/AN/A Do institutionals & insiders hold more shares of MAAQ or ALZN? 68.4% of Mana Capital Acquisition shares are owned by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are owned by institutional investors. 30.2% of Alzamend Neuro shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media prefer MAAQ or ALZN? In the previous week, Alzamend Neuro had 3 more articles in the media than Mana Capital Acquisition. MarketBeat recorded 3 mentions for Alzamend Neuro and 0 mentions for Mana Capital Acquisition. Alzamend Neuro's average media sentiment score of 0.51 beat Mana Capital Acquisition's score of 0.00 indicating that Alzamend Neuro is being referred to more favorably in the news media. Company Overall Sentiment Mana Capital Acquisition Neutral Alzamend Neuro Positive SummaryAlzamend Neuro beats Mana Capital Acquisition on 6 of the 9 factors compared between the two stocks. Get Alzamend Neuro News Delivered to You Automatically Sign up to receive the latest news and ratings for ALZN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALZN vs. The Competition Export to ExcelMetricAlzamend NeuroMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.95M$3.00B$5.50B$9.69BDividend YieldN/A2.29%4.64%4.14%P/E RatioN/A19.9630.3925.31Price / SalesN/A354.89447.48103.25Price / CashN/A40.7837.7258.50Price / Book0.497.658.306.01Net Income-$4.51M-$54.75M$3.26B$265.10M7 Day Performance2.52%-0.15%0.91%1.13%1 Month Performance-23.75%8.12%3.66%2.44%1 Year Performance-87.68%24.55%46.29%27.98% Alzamend Neuro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALZNAlzamend Neuro3.1657 of 5 stars$2.44+1.7%$180.00+7,277.0%-87.5%$6.95MN/A0.004Analyst DowngradeMAAQMana Capital AcquisitionN/A$3.45-10.9%N/A+679.3%$28.03MN/A0.001High Trading VolumeGBIOGeneration Bio4.2242 of 5 stars$4.04-0.1%$80.00+1,881.7%-82.8%$27.30M$19.89M-0.38150News CoveragePositive NewsEarnings ReportUpcoming EarningsOKUROnKure Therapeutics3.4546 of 5 stars$1.99-2.0%$32.33+1,525.6%N/A$26.87MN/A-0.38N/ANews CoverageEarnings ReportRNTXRein TherapeuticsN/A$1.14-1.7%N/AN/A$26.28MN/A-0.409DYAIDyadic International3.3066 of 5 stars$0.86+6.4%$6.00+596.1%-39.1%$25.94M$3.49M-4.317News CoverageBDRXBiodexa Pharmaceuticals0.2606 of 5 stars$7.04+2.0%N/AN/A$25.59M$470K0.0020Positive NewsGap UpMIRAMIRA Pharmaceuticals2.2989 of 5 stars$1.48+3.9%$17.00+1,052.5%-32.4%$25.04MN/A-2.902News CoverageGap UpNNVCNanoViricides0.2598 of 5 stars$1.54-0.3%N/A-18.5%$24.67MN/A-2.1320TENXTenax Therapeutics2.1115 of 5 stars$5.87+0.3%$17.50+198.1%+44.4%$24.36MN/A-2.379JATTJATT AcquisitionN/A$1.41-0.7%N/A-58.1%$24.32MN/A0.003Gap UpHigh Trading Volume Related Companies and Tools Related Companies Mana Capital Acquisition Competitors Generation Bio Competitors OnKure Therapeutics Competitors Rein Therapeutics Competitors Dyadic International Competitors Biodexa Pharmaceuticals Competitors MIRA Pharmaceuticals Competitors NanoViricides Competitors Tenax Therapeutics Competitors JATT Acquisition Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALZN) was last updated on 8/12/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredElon Musk: “Nothing happens without this…”Lithium has fueled the EV boom, but another resource is even more critical. Without it, over 20 million electr...Behind the Markets | SponsoredSell these stocks now—what to buy insteadSell these stocks now—Here’s what to buy instead Wall Street legend Marc Chaikin says you must know these 3...Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredAmericans are rushing into gold (but not billionaires!)Billionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alzamend Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alzamend Neuro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access